Insulin Dose Adjustment in Patients with Chronic Kidney Disease and Type 2 Diabetes

Introduction to Insulin Dose Adjustment

• The American College of Endocrinology recommends reducing total daily insulin dose by 50% in patients with Type 2 Diabetes and Chronic Kidney Disease (CKD) stage 5, due to impaired insulin clearance and increased hypoglycemia risk 1
• Patients with CKD and Type 2 Diabetes require careful insulin dose adjustment to balance glycemic control and hypoglycemia risk, with a recommended HbA1c target of 7.0-7.5% 3

Critical Assessment of Current Insulin Regimen

• The patient's current insulin regimen, with a total daily dose of 45 units, represents a high hypoglycemia risk, particularly in the context of CKD and an HbA1c of 4.9% 2
• CKD significantly impairs insulin clearance, leading to prolonged insulin action and increased hypoglycemia risk, even with previously appropriate doses 1

Recommended Insulin Adjustment Algorithm

• The Endocrine Society recommends reducing basal insulin by 35-40% for patients with Type 1 Diabetes and CKD stage 5, and reducing total daily dose by 50% for those with Type 2 Diabetes and CKD stage 5 1
• On hemodialysis days, an additional 25% reduction in basal insulin dose is recommended for patients on dialysis 1

Monitoring Strategy for Glycemic Control

• The Kidney International journal suggests implementing daily self-monitoring of blood glucose (SMBG) at minimum: fasting, pre-meals, and bedtime, to detect asymptomatic hypoglycemia that HbA1c may not reflect accurately in CKD 3
• Continuous glucose monitoring (CGM) is strongly preferred over SMBG in this population to capture nocturnal and asymptomatic hypoglycemia episodes 3

Target Glycemic Goals and Alternative Treatment Considerations

• The American Journal of Kidney Diseases recommends a revised HbA1c target of 7.0-7.5% for patients with CKD, to balance glycemic control with hypoglycemia risk 4
• Fasting glucose target should be 90-130 mg/dL, and postprandial glucose target should be <180 mg/dL 4
• Prioritizing avoidance of hypoglycemia over tight glycemic control is crucial in this population, given increased morbidity and mortality risk 3

Critical Pitfalls to Avoid in Insulin Dose Adjustment

• Continuing current insulin doses despite HbA1c <5.0% will inevitably lead to severe hypoglycemia, which carries higher mortality risk in CKD patients 3
• Relying solely on HbA1c for glycemic assessment in advanced CKD without SMBG or CGM data will miss dangerous hypoglycemic episodes 3
• Failing to account for reduced insulin clearance in CKD when calculating doses leads to insulin accumulation and prolonged hypoglycemia 1

Urgent Safety Measures for Hypoglycemia

• Prescribing a glucagon emergency kit and educating the patient/family on recognition and treatment of severe hypoglycemia is essential 2
• Instructing the patient to carry 15-20 grams of fast-acting carbohydrate at all times is recommended 2
• If any hypoglycemic episode occurs, reducing insulin dose by an additional 10-20% immediately is necessary 2